Meeting
2024 ASCO Gastrointestinal Cancers Symposium
A randomized controlled phase III study comparing surgery alone versus adjuvant nivolumab versus adjuvant S-1 for locally advanced esophageal cancer with no pathological complete response: JCOG2206 (SUNRISE Trial).
Authors
Satoru Matsuda
Department of Surgery, Keio University School of Medicine, Tokyo, Japan
Satoru Matsuda , Ryosuke Kita , Motoo Nomura , Yuko Kitagawa , Ken Kato , Rei Goto , Takashi Yoshioka , Shun Yamamoto , Takahiro Tsushima , Ryunosuke Machida , Keita Sasaki , Haruhiko Fukuda , Hiroya Takeuchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
jRCTs031230219
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr TPS417)
DOI
10.1200/JCO.2024.42.3_suppl.TPS417
Abstract #
TPS417
Poster Bd #
N2
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Safety and short-term efficacy of adjuvant nivolumab after neoadjuvant docetaxel, cisplatin, and fluorouracil for locally advanced esophageal squamous cell carcinoma.
First Author: Mashiro Okunaka
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Short-term safety of adjuvant nivolumab therapy after neoadjuvant docetaxel plus cisplatin and 5-FU therapy for locally advanced esophageal squamous cell carcinoma.
First Author: Toshiharu Hirose
Poster
2022 ASCO Annual Meeting
Phase 3 randomized study comparing docetaxel-platinum with docetaxel-platinum-5 fluorouracil as neoadjuvant chemotherapy in technically unresectable oral cancer.
First Author: Ajaykumar Singh
Poster
2021 Gastrointestinal Cancers Symposium
FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma (JCOG1804E)—The short-term results of cohort A and B.
First Author: Shun Yamamoto